[Research Progress of Targeted Therapy for BRAF Mutation 
in Advanced Non-small Cell Lung Cancer].

Abstract excerpt

Targeted therapy is one of the major treatment modalities in advanced non-small cell lung cancer (NSCLC) with sensitive driver gene mutations. BRAF is considered a promising oncogenic driver in NSCLC after the discovery of epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) fusion and ROS1 rearrangement. BRAF V600E mutation accounts for more than half of BRAF mutations, which is a...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to ALK gene
• Share to Carcinoma, Non-Small-Cell Lung
• Share to Drug Resistance, Neoplasm